BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Syntarga BV Closes Series A Financing


10/19/2005 5:12:42 PM

Nijmegen, The Netherlands April 15, 2005 Syntarga BV today announced that it has realised a first round of financing. Allocation of funds will be towards the development of novel linker technologies for oncology products and the establishment of partnerships with biotechnology and pharmaceutical companies. The financing round was led by Aglaia Oncology Fund with BioPartner Start-up Ventures as co-investor.

Many anti-cancer agents, either used in the clinic or in development, cause serious side effects or are even too toxic for direct use. To contribute to the solution of this problem, Syntarga was founded in 2002 as a spin-off from the Department of Organic Chemistry at the Radboud University in Nijmegen. Its approach is to link anti-cancer drugs to targeting molecules via chemistries that enable an efficiently triggered release of the cell-killing drug moiety upon localization of the conjugate at the tumor site. Syntarga’s unique technologies thereby serve to improve the efficacy and to reduce the toxicity of these agents. Appropriate linker chemistries are essential to unlock the therapeutic success of many new, targeted bioconjugates based on peptides, proteins or antibodies with tumor-specific binding properties. Syntarga aims to become a leader in the development of sophisticated novel linker technologies to achieve successful bioconjugation and targeted drug release.

Aglaia is a venture firm dedicated to identifying groundbreaking opportunities in cancer research and to contributing to the expansion of its ventures into next phases. Aglaia’s team, expertise and network in the field of oncology research and product development further support the growth of Syntarga.

BioPartner Start-up Ventures is a fund initiated by the Dutch Ministry of Economic Affairs, aiming at facilitating venture capital investments in the life sciences sector. Other shareholders include the founders, the Radboud University and Biorogen BV.

For further information contact: Syntarga Vincent de Groot, Ph.D. - CEO fmhdegroot@syntarga.com www.syntarga.com Aglaia Biomedical Ventures info@aglaia-biomedical.com www.aglaia-biomedical.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES